Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $20,825.61 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $26.13, for a total transaction of $20,825.61. Following the completion of the transaction, the director directly owned 23,884 shares in the company, valued at approximately $624,088.92. This represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Down 3.0%

Shares of Pelthos Therapeutics stock opened at $27.16 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79. The company has a market cap of $94.52 million, a P/E ratio of -1.32 and a beta of 3.10. The stock’s 50 day moving average price is $26.87. Pelthos Therapeutics Inc. has a 1-year low of $16.20 and a 1-year high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The company had revenue of $10.91 million for the quarter. Research analysts forecast that Pelthos Therapeutics Inc. will post -12.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PTHS shares. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Oppenheimer lifted their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Cantor Fitzgerald assumed coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating and a $50.00 target price for the company. Finally, Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Pelthos Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

Institutional Trading of Pelthos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Knott David M Jr raised its holdings in Pelthos Therapeutics by 9.3% during the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after purchasing an additional 1,792 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after buying an additional 3,295 shares during the period. Persistent Asset Partners Ltd increased its position in shares of Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after buying an additional 3,604 shares during the period. Pale Fire Capital SE raised its stake in Pelthos Therapeutics by 59.5% during the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock worth $271,000 after buying an additional 4,819 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Pelthos Therapeutics in the fourth quarter valued at $343,000. Institutional investors and hedge funds own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).